Rome Protocol has introduced Hadrian, a testnet running on Solana Devnet, allowing developers to build and test Ethereum-style applications using Solidity within Solana's environment. Hadrian uses test USDC for gas fees, with configurable pricing set by network operators, and supports atomic and iterative transaction execution modes. The project also lists Rubicon as its mainnet, using real USDC. Reference implementations include Compound v3 and Aave v3 demos, though no official migrations are confirmed. Rome's EVM runs Solidity code via a Solana program, enabling cross-program calls and Ethereum tool compatibility. The network has undergone a Halborn audit, but some Ethereum features differ, and transaction limits apply. This development could enhance Solana's DeFi ecosystem by bridging Ethereum compatibility and Solana's speed and cost advantages.
Rome Protocol's new Hadrian testnet on Solana offers Ethereum-compatible development, providing context for readers following blockchain innovation. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 21:22 WIB: 40 out of 50 major cryptocurrencies rose today. SUSHI rose 3.25% to Rp3.892 with 86% buy orders, UNI increased 2.89% to Rp130.670 with 86% sell orders, and SNX gained 2.76% to Rp3.868 with nearly balanced order activity.
Miracles, a personalized children's book maker, has printed more than 100,000 books, serving over 45,000 families. Each book features a unique 3D character of the child, created from a single photo, making the child the hero of the story. Books for U...
Miracles, a company specializing in personalized children's books where each child becomes the story's hero, has printed over 100,000 books for more than 45,000 families. The books are printed locally in Germany and delivered within a few days, offer...
The global migraine market is projected to expand at a 6% annual growth rate through 2036, driven by rising migraine prevalence, better diagnosis, and awareness. Innovative treatments beyond traditional CGRP inhibitors, including PACAP-targeted thera...
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
